Proton therapy for hepatocellular carcinoma

Ling, Ted C.; Kang, Joseph I.; Bush, David A.; Slater, Jerry D.; Yang, Gary

doi:10.1007/s11670-012-0276-7

Cited by 22 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is in line with the known adverse prognostic significance of ascites for both cirrhosis and HCC (23,24). In addition, ascites complicates radiotherapy planning and delivery (25). Thus, HCC-directed SBRT in the setting of severe cirrhosis has a low probability of success.…”

Section: Discussionsupporting

confidence: 59%

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

2018

View full text Add to dashboard Cite

Background/Aim: Our study reviewed the results of patients with hepatocellular carcinoma and Child-Pugh score 8-11 cirrhosis treated with stereotactic body radiotherapy when liver transplant was not an option. Patients and Methods: A retrospective review was performed on 15 patients with Child-Pugh class B and C cirrhosis treated with stereotactic body radiotherapy. The median total dose was 35 Gy in 4-5 fractions. None were listed for a liver transplant due to either being outside of the Milan criteria or to medical contraindications. Results: The overall survival was 26.7% at 6 months, with a mean survival of 152 days. The mean survival with and without ascites was 3.3 months and 8.3 months, respectively. Conclusion: For hepatocellular carcinoma with cirrhosis of Child-Pugh score 8 or more, prognosis after liver stereotactic body radiotherapy was suboptimal. While irradiation achieved local tumor control, progressive cirrhosis was a common cause of death. Patients without ascites at the time of radiotherapy had the best prognosis.

show abstract

Section: Discussionsupporting

confidence: 59%

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

2018

View full text Add to dashboard Cite

show abstract

“…Particle radiotherapy has seen an increasing role in the treatment of hepatocellular carcinoma due to the potential of increased normal-liver sparing [143]. Often hypofractionated regimens are applied [52,144,145].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Deep Inspiration Breath Hold—Based Radiation Therapy: A Clinical Review

Boda-Heggemann

Knopf

Simeonova-Chergou

et al. 2016

International Journal of Radiation Oncology*Biology*Physics

200

148

View full text Add to dashboard Cite

“…Although there have been many advances in HCC therapy, such as recent target therapies, liver transplantation, proton therapy and interventional radiological treatment, the overall patient outcome has not been improved substantially. The 5‐year survival rate is limited to 25–39% after surgery . Therefore, novel treatments for liver cancer are urgently needed .…”

mentioning

confidence: 99%

Antitumor efficacy of C‐X‐C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo

et al. 2013

View full text Add to dashboard Cite

C-X-C motif chemokine ligand 14 (CXCL14) is a novel gene that is expressed in many normal cells but is absent from or expressed at very low levels in cancerous tissues such as head and neck squamous cell carcinoma (HNSCC), prostate cancer, and pancre-atic cancer. However, the relationship between CXCL14 and hepa-tocellular carcinoma (HCC) remains unclear. Therefore, the exact function of CXCL14, which may modulate antitumor immune responses in certain cancers, was evaluated. CXCL14 was down-regulated in HCC tissues compared to adjacent normal tissues. Moreover, overexpression of CXCL14 had an inhibitory effect on cell proliferation, induced apoptosis and inhibited the invasion of HCC cells in vitro. Upregulation of CXCL14 by lentivirus also significantly suppressed the growth of subcutaneous tumors in nude mice in vivo. We further demonstrated that the loss of CXCL14 expression was regulated by promoter hypermethylation. CXCL14 induced tumor cell apoptosis through both the mitochon-drial and nuclear apoptosis pathways. CXCL14 suppressed tumor cell proliferation through regulation of the cell cycle by down-regulation of cyclins and cyclin-dependent kinases. In conclusion, CXCL14 plays a pivotal role as a potential tumor suppressor in HCC. The re-expression or upregulation of this gene may provide a novel strategy in HCC therapy in the future. (Cancer Sci 2013; 104: 1523-1531) H epatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related deaths worldwide. Eighty-two percent of cases (and deaths) are in developing countries and the death rate is the second highest in China because of the high prevalence of chronic hepatitis B virus infection and liver cirrhosis. (1-3) Japan, unlike other Asian countries, has a high proportion of HCC caused by hepatitis C virus (HCV) infection accounting for 80-90% of all cases. (4) Although there have been many advances in HCC therapy, such as recent target therapies, liver transplantation, proton therapy and interventional radiological treatment, the overall patient outcome has not been improved substantially. The 5-year survival rate is limited to 25-39% after surgery. (5-9) Therefore, novel treatments for liver cancer are urgently needed. (10,11) New treatments such as immuno-therapy and potential novel gene therapy show potential for the treatment of HCC. (12,13) Recent studies have suggested important functions of chemo-kines in various aspects of tumor growth. (14) Chemokines contribute to leukocyte infiltration in tumors, and some chemokines, such as IL-8, CXCL1-3 and CXCL5, also have direct proangiogenic effects. In addition, chemokines, especially the CXC family, are potentially important factors in tumor growth, immunity, invasion, metastasis and potent mediators of neoangiogenesis. (15-17) The chemokine C-X-C motif chemokine ligand 14 (CXCL14), was initially named BRAK because of its isolation from the human breast and kidney-derived cells; however, its function and receptor remain unclear. (18-20) CXCL14 was reported t...

show abstract

Proton therapy for hepatocellular carcinoma

Cited by 22 publications

References 35 publications

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant

Deep Inspiration Breath Hold—Based Radiation Therapy: A Clinical Review

Antitumor efficacy of C‐X‐C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo

Contact Info

Product

Resources

About